gonadotropin-releasing hormone agonist + human chorionic gonadotropin + human menopausal gonadotropin

This is a combination therapy used primarily in fertility treatments, particularly for assisted reproductive technologies like in vitro fertilization (IVF). The combination works synergistically to control ovarian stimulation and egg maturation. **Gonadotropin-releasing hormone (GnRH) agonists** work by initially stimulating and then suppressing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland. This creates a controlled hormonal environment that prevents premature ovulation during fertility treatments[6][7]. Common GnRH agonists include leuprolide acetate (Lupron), nafarelin acetate (Synarel), and goserelin acetate (Zoladex)[7][9]. **Human chorionic gonadotropin (hCG)** is used to mimic the natural LH surge that occurs in the menstrual cycle, finalizing the maturation of eggs and triggering their release during ovulation[4][5]. It's typically administered once follicles have reached an appropriate size. Common brands include Pregnyl, Ovidrel, and Novarel[4][5]. **Human menopausal gonadotropin (hMG)** contains a combination of FSH and LH, which stimulate the ovaries to produce multiple follicles and eggs[4][5]. Common brands include Menopur and Repronex[4][5]. When used together in fertility protocols, these medications allow for precise control of the ovulation cycle, maximizing the chances of successful egg retrieval and fertilization.